CD19


Also found in: Wikipedia.

CD19

a type I transmembrane protein found on all B cells and B-cell precursors and some follicular dendritic cells that acts as an accessory molecule for B-cell signal transduction; expressed in all B-cell neoplasms.
References in periodicals archive ?
FT596 is derived from a clonal master induced pluripotent stem cell line engineered with three functional modalities designed to optimize anti-tumor activity: a proprietary CAR targeting B-cell antigen CD19; a novel high-affinity 158V, non-cleavable CD16 Fc receptor; and an interleukin-15 receptor fusion.
ADCT-402 (loncastuximab tesirine) is an antibody drug conjugate comprised of a humanized monoclonal antibody that binds to human CD19, conjugated through a linker to a pyrrolobenzodiazepine dimer toxin.
Immunotherapy company NantKwest Inc (Nasdaq:NK) said on Monday that it plans to launch its first-in-human clinical trial targeting CD19 t-haNK in advanced B-cell lymphoma following the US FDA review of its investigational new drug application (IND).
Global Banking News-June 4, 2019-NantKwest to begin first-in-human clinical trial targeting CD19 t-haNK in advanced B-cell lymphoma
the CAR), consisting of an extracellular antigen-recognising receptor (targeting CD19 on B-cells in this therapeutic application) coupled to intracellular signalling domains that allow T-cell activation following recognition of the antigen.
B-cell malignancies express specific tumour associated antigens including CD19. T-cells can be genetically engineered to express a chimeric antigen receptor (CAR) that recognizes the B-cell antigen CD19.2 CD19 is expressed on developing and mature B-cells, absent on pluripotent haematopoietic stem cells and highly retained over the process of neoplastic transformation.
CD19 negative precursor B acute lymphoblastic leukemia (B-ALL)-Immunophenotypic challenges in diagnosis and monitoring: A study of three cases.
After PBMC isolation, the resulting cell suspension was distributed into individual tubes with an amount of 1 x [10.sup.6]/sample, and the samples were incubated with a combination of the following mAbs: CD45 FITC/CD14 PE, Cy-Chrome Mouse Anti-Human CD3, FITC Mouse Anti-Human CD19, FITC Mouse Anti-Human CD4, FITC Mouse Anti-Human CD8, PE Mouse Anti-Human CD279 (PD-1), and PE Mouse Anti-Human CD274 (PD-L1), all of which came from BD Biosciences (USA).
Single-cell suspensions of murine splenocytes were prepared by manual disruption of total spleens, and highly purified B lymphocytes were isolated by immunomagnetic positive selection according to the manufacturer's instructions (STEMCELL Technologies, EasySep[TM] Mouse CD19 positive selection kit II, Grenoble, France).
The results were as follows: Flow cytometric immunophenotyping identifies a phenotypically distinct population of cells with low light scatter properties that express CD19, low density CD20, CD5, and CD45 and display Kappa immunoglobulin light chain restriction.
The peripheral blood mononuclear cells were isolated by standard Ficoll-Paque Plus density-gradient centrifugation, and the following monoclonal antibodies were used for human fluorescence-activated cell staining according to the manufacturer's instruction: APC-Cy7-conjugated antihuman CD19 (HIB19), PE-Cy7-conjugated anti-human CD5 (LT21), APC-conjugated anti-human CD1d (51.1), and PerCP-Cy5.5-conjugated anti-human CD23 (EBVCS-5), all from Biolegend.